# A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT01106599** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 61 (actual)

## Conditions studied

- Solid Cancers

## Interventions

- **DRUG:** GDC-0623

## Key facts

- **NCT ID:** NCT01106599
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01106599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01106599, "A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01106599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*